Methohexital en es it fr

Methohexital Brand names, Methohexital Analogs

Methohexital Brand Names Mixture

  • No information avaliable

Methohexital Chemical_Formula


Methohexital RX_link

Methohexital fda sheet

Methohexital FDA

Methohexital msds (material safety sheet)

Methohexital Synthesis Reference

No information avaliable

Methohexital Molecular Weight

262.304 g/mol

Methohexital Melting Point

No information avaliable

Methohexital H2O Solubility

No information avaliable

Methohexital State


Methohexital LogP


Methohexital Dosage Forms

Powder for solution

Methohexital Indication

Indicated for use as an intravenous anaesthetic.

Methohexital Pharmacology

Methohexital, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.

Methohexital Absorption

The absolute bioavailability following rectal administration of methohexital is 17%.

Methohexital side effects and Toxicity

The onset of toxicity following an overdose of intravenously administered methohexital will be within seconds of the infusion. If methohexital is administered rectally or is ingested, the onset of toxicity may be delayed. The manifestations of an ultrashort-acting barbiturate in overdose include central nervous system depression, respiratory depression, hypotension, loss of peripheral vascular resistance, and muscular hyperactivity ranging from twitching to convulsive-like movements. Other findings may include convulsions and allergic reactions. Following massive exposure to any barbiturate, pulmonary edema, circulatory collapse with loss of peripheral vascular tone, and cardiac arrest may occur.

Methohexital Patient Information

When appropriate, patients should be instructed as to the hazards of drowsiness that may follow use of barbiturates. Outpatients should be released in the company of another individual, and no skilled activities, such as operating machinery or driving a motor vehicle, should be engaged in for 8 to 12 hours.

Methohexital Organisms Affected

Humans and other mammals